/

Società

Sy

Non verificato

Synthekine Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

7 comunicati stampa

Guarda tutti i comunicati

13/11/2025

Industria

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

First Patient Dosed in SYNERGY-101, a Global, Randomized Phase 2 Clinical Trial of STK-012 in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

Fonte

Synthekine Inc.

Emittente

1.00

0

07/11/2025

Eventi

Industria

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

Fonte

Synthekine Inc.

Emittente

1.00

0

30/10/2025

Scienza

Biotecnologia

Medicina - Varie

Sanità

Farmaceutica

Salute

Oncologia

Analisi di mercato

Synthekine Announces Late-Breaking Oral Presentation of Initial Clinical Data of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous NSCLC at SITC 2025 Annual Meeting

Fonte

Synthekine Inc.

Emittente

1.00

0

09/12/2024

Scienza

Medicina - Varie

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

Eventi

Fiere

Industria

Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting

Fonte

Synthekine Inc.

Emittente

1.00

0

15/11/2024

Eventi

Industria

Oncologia

Salute

Sanità

Scienza

Biotecnologia

Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024

Fonte

Synthekine Inc.

Emittente

1.00

0

08/11/2024

Industria

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

Synthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Fonte

Synthekine Inc.

Emittente

1.00

0

04/09/2024

Industria

Scienza

Biotecnologia

Farmaceutica

Sanità

Salute

Igiene alimentare

Medicina - Varie

Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion

Fonte

Synthekine Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0